联合[18F]-FDG PET-MR显像用于监测小肠克罗恩病
这项前瞻性初步研究纳入35例临床疑似小肠克罗恩病患者,以小肠胶囊内镜确诊,临床医生在不知晓PET结果的情况下依据标准诊断启动治疗。18例患者在3个月时完成随访[18F]-FDG PET-MRE,最大SUV中位数从基线3.2降至2.1(p=0.0025),sMARIA评分亦显著降低(p=0.001),粪便钙卫蛋白中位数从451 µg/g降至163 µg/g(p=0.004)。研究提示[18F]-FDG PET-MRE可能有助于评估新诊断小肠克罗恩病的生化治疗反应。
要点
- 18例完成3个月随访PET-MRE者最大SUV中位数由3.2降至2.1(p=0.0025)。
- 随访时sMARIA评分较基线显著降低(p=0.001)。
- 粪便钙卫蛋白中位数由451 µg/g降至163 µg/g(p=0.004)。
核心结论
- 这项初步前瞻性研究提示,[18F]-FDG PET-MRE可能有助于评估新诊断小肠克罗恩病的生化治疗反应。
研究设计与样本
- 前瞻性初步研究,招募35例临床疑似小肠克罗恩病的志愿者患者,均行回结肠镜检查、实验室检查及[18F]-FDG PET-MRE,克罗恩病诊断由小肠胶囊内镜确认。
- 临床医生依据标准诊断启动治疗,且不知晓PET结果;18例患者在3个月时完成随访[18F]-FDG PET-MRE。
- 试验注册号NCT06796959(ClinicalTrials.gov),于2025年1月21日回顾性注册,首例受试者入组时间为2020年8月1日。
主要发现
- 最大SUV中位数从基线至随访显著下降(3.2 vs 2.1,p=0.0025)。
- 简化磁共振活动指数(sMARIA)在随访时亦显著降低(p=0.001)。
- 粪便钙卫蛋白中位数下降(451 µg/g vs 163 µg/g,p=0.004)。
局限性
- 原文称本研究为初步研究(preliminary)。
- 原文指出[18F]-FDG PET-MRE在监测治疗反应中的作用此前尚未确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Crohn's disease (CD) is a chronic and relapsing inflammatory disease of the gastrointestinal tract. Diagnostics and follow-up are difficult in small bowel, that can be only partially evaluated by conventional endoscopy. Combined positron emission tomography magnetic resonance enterography (PET-MRE) has shown potential in diagnosing small bowel CD, but its role in monitoring treatment response has not been previously established. This study aimed to evaluate whether PET-MRE can be used to assess the efficacy of medical therapy. We hypothesized that standardized uptake values (SUV) in inflamed small bowel segments would decrease following initiation of standard therapy. A total of 35 volunteer patients with clinically suspected small bowel CD were recruited. All patients underwent ileocolonoscopy and laboratory testing, followed by [18F]-FDG PET-MRE. CD diagnosis was confirmed by small bowel capsule endoscopy. Clinicians initiated treatment based on standard diagnostics, blinded to the PET results. Eighteen patients completed follow-up [18F]-FDG PET-MRE at three months. Maximum SUV (SUVMax) was measured in the small intestine and compared with MRE findings. The median SUVMax decreased significantly from baseline to follow-up (3.2 vs. 2.1, p = 0.0025). The Simplified Magnetic Resonance Index of Activity (sMARIA) was also significantly lower at follow-up (p = 0.001). Representatively, median fecal calprotectin declined (451 µg/g vs. 163 µg/g, p = 0.004). This preliminary prospective study suggests that [18F]-FDG PET-MRE may be a useful tool for assessing biochemical response to treatment in newly diagnosed small bowel CD.Trial registration number: NCT06796959 (ClinicalTrials.gov). Retrospectively registered on 21.1.2025. Enrollment of first participant on 1.8.2020.
引用
- Mattila J, Kallio J, Löyttyniemi E, et al. Combined [18F]-FDG PET-MR imaging for monitoring small bowel crohn's disease. Eur J Nucl Med Mol Imaging. 2025. PMID: 40856818. doi:10.1007/s00259-025-07524-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。